Open AccessSteady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected Individuals
Author(s) -
Agnes I. Veldkamp,
Rolf P. G. van Heeswijk,
J. Mulder,
Pieter L. Meenhorst,
G. Schreij,
S. van der Geest,
Joep M. A. Lange,
Jos H. Beijnen,
Richard M. W. Hoetelmans
Publication year - 2001
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00126334-200108010-00004
Subject(s) - pharmacokinetics , saquinavir , ritonavir , crossover study , cmax , pharmacology , regimen , medicine , dosing , bioequivalence , capsule , viral load , human immunodeficiency virus (hiv) , placebo , virology , antiretroviral therapy , biology , botany , alternative medicine , pathology
To compare the steady state plasma pharmacokinetics of 1000 mg of saquinavir (SQV) in a soft-gel capsule (SGC) formulation in combination with 100 mg of ritonavir (RTV) (capsules) in a twice-daily dosing regimen in HIV-1-infected individuals with historical controls who used 400 mg of SQV in a hard-gel capsule (HGC) formulation in combination with 400 mg of RTV and to investigate the plasma pharmacokinetics of the 1000 mg/100 mg regimen after normal and high-fat breakfasts.